Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of Target Enrichment Platforms for Circulating Tumor DNA Detection.

Scientific reports - 5 Mar 2020

Lam So Ngo, Zhou Ying Chun, Chan Yee Man, Foo Ching Man, Lee Po Yi, Mok Wing Yeung, Wong Wing Sum, Fung Yan Yee, Wong Kit Yee, Huang Jun Yuan, Chow Chun Kin

Abstract excerpt

Cancer-related mortality of solid tumors remains the major cause of death worldwide. Circulating tumor DNA (ctDNA) released from cancer cells harbors specific somatic mutations. Sequencing ctDNA opens opportunities to non-invasive population screening and lays foundations for personalized therapy. In this study, two commercially available platforms, Roche's Avenio ctDNA Expanded panel and QIAgen's QIAseq Human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Base Composition
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Genomics and Diagnostics

Share to Circulating Tumor DNA

Share to DNA, Neoplasm

Share to Genetic factors in colorectal cancer

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 32139724
DOI: 10.1038/s41598-020-60375-x
PMCID: PMC7057974

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of Target Enrichment Platforms for Circulating Tumor DNA Detection.PMID 32139724Read ↗

Strategies for improving detection of circulating tumor DNA using next generation sequencing.Semantic proximity Read ↗

Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors.Semantic proximity Read ↗

Detection of Circulating Tumor DNA in Plasma Using Targeted Sequencing.Semantic proximity Read ↗

Analytical evaluation of circulating tumor DNA sequencing assays.Semantic proximity Read ↗

Validation and clinical evaluation of a comprehensive circulating tumor DNA assay for genomic profiling in solid tumorsSemantic proximity Read ↗

Analytical performance evaluation of a commercial next generation sequencing liquid biopsy platform using plasma ctDNA, reference standards, and synthetic serial dilution samples derived from normal plasma.Semantic proximity Read ↗

Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer DetectionSemantic proximity Read ↗

Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden.Semantic proximity Read ↗

Analytical validation and clinical utilization of K-4CARE<sup>TM</sup>: a comprehensive genomic profiling assay with personalized MRD detectionSemantic proximity Read ↗

Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies.Semantic proximity Read ↗

Noninvasive MRD monitoring and profiling of clonal evolution by ctDNA in patients with advanced cancers treated within molecular tumor boardsSemantic proximity Read ↗

Utilizing Plasma Circulating Tumor DNA Sequencing for Precision Medicine in the Management of Solid Cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.